Active, not recruitingPHASE1, PHASE2NCT04520269

A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)

Studying Hereditary breast cancer

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National University Hospital, Singapore
Principal Investigator
Joline Si Jing Lim
National University Hospital, Singapore
Intervention
Pacritinib(drug)
Enrollment
74 enrolled
Eligibility
21-99 years · All sexes
Timeline
20202026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04520269 on ClinicalTrials.gov

Other trials for Hereditary breast cancer

Additional recruiting or active studies for the same condition.

See all trials for Hereditary breast cancer

← Back to all trials